Abstract | PURPOSE: Increased coagulation has been associated with cancer onset and progression. Mainly small studies have addressed the association between clotting factor gene polymorphisms and the onset of colorectal cancer. We examined the association between six well-known clotting factor gene polymorphisms and colorectal cancer risk in a large case-control study. PATIENTS AND METHODS: RESULTS: Homozygous carriers of the prothrombotic factor V Leiden polymorphism showed a 5.8-fold increased risk (95% CI, 1.69 to 19.72) for colorectal cancer compared with noncarriers. A 30% reduced risk was found for heterozygous carriers of factor V Leiden (OR = 0.68; 95% CI, 0.52 to 0.90) and prothrombin G20210A (OR = 0.69; 95% CI, 0.49 to 0.96), implying an advantage for slightly increased thrombin generation. Carriers of the antithrombotic factor XIII Val34Leu polymorphism showed a 15% reduced risk of developing colorectal cancer (OR = 0.85; 95% CI, 0.74 to 0.97) compared with noncarriers. Our results did not support an effect of PAI-1 4G/5G, MTHFR 677C>T, and fibrinogen gamma 10034C>T on colorectal cancer risk. CONCLUSION:
|
Authors | Carla Y Vossen, Michael Hoffmeister, Jenny C Chang-Claude, Frits R Rosendaal, Hermann Brenner |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 29
Issue 13
Pg. 1722-7
(May 01 2011)
ISSN: 1527-7755 [Electronic] United States |
PMID | 21422408
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Coagulation Factors
- factor V Leiden
- Factor V
- Prothrombin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Blood Coagulation Factors
(genetics)
- Case-Control Studies
- Colorectal Neoplasms
(genetics)
- Factor V
(genetics)
- Female
- Heterozygote
- Homozygote
- Humans
- Male
- Middle Aged
- Polymorphism, Genetic
- Prothrombin
(genetics)
- Risk
|